Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Receivables: 2022-2024

Historic Change in Receivables for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Dec 2024 value amounting to -$332,000.

  • Monte Rosa Therapeutics' Change in Receivables rose 129.14% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 925.82%. This contributed to the annual value of -$332,000 for FY2024, which is 82.50% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Change in Receivables stood at -$332,000 for FY2024, which was up 82.50% from -$1.9 million recorded in FY2023.
  • Monte Rosa Therapeutics' Change in Receivables' 5-year high stood at $187,000 during FY2022, with a 5-year trough of -$1.9 million in FY2023.
  • Its 3-year average for Change in Receivables is -$680,667, with a median of -$332,000 in 2024.
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 1,114.44% in 2023, then surged by 82.50% in 2024.
  • Yearly analysis of 3 years shows Monte Rosa Therapeutics' Change in Receivables stood at $187,000 in 2022, then slumped by 1,114.44% to -$1.9 million in 2023, then skyrocketed by 82.50% to -$332,000 in 2024.